A new startup from one of the key scientists at Google DeepMind exits stealth today with $50 million in funding.
Alphabet’s Google DeepMind and its sister company Isomorphic Labs have created a new AI model that they say can help predict both the structure and interaction of most molecules involved in ...
Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein ...
Google parent Alphabet has drawn on its DeepMind artificial intelligence division to form a drug discovery unit that it calls Isomorphic Labs. The UK-registered company will be able to tap into ...
Among the most important aspects of this story is AlphaFold, the artificial intelligence and foundation model platform developed by Google DeepMind and Isomorphic Labs, both Alphabet companies.
Google's DeepMind spinoff Isomorphic Labs expects clinical trial of drugs it designed using AI to start this year, Bloomberg News reported, citing the company's CEO Demis Hassabis. Isomorphic is ...
Isomorphic Labs aims to start clinical trials for AI-designed drugs by year-end, potentially revolutionizing drug discovery timelines. Market optimism persists under Trump 2.0, with a focus on big ...
"At the same time, I saw that with the launch of Isomorphic Labs, and their plans based on AlphaFold2, that they were starting many things at once. I felt like the opportunity was really in going ...